This existing GMP compliant facility, located at Bharuch (Unit-1) with ongoing expansion part of the company's strategic capex initiative
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Ayush is expanding beyond wellness to therapeutic wellness
A 'better for you' organic brand spanning Food & Beverages and Nutraceutical categories
GMM Pfaudler US completes acquisition of MixPro
he company posted total income during Q2 FY24 at Rs. 12.86 crore
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
KNISS has established a solid foundation of trust in the customers' minds, delivering high quality Products uncompromisingly.
Subscribe To Our Newsletter & Stay Updated
